Jeffrey E Grice

List of Publications by Year
in descending order

125	5,165	94269	95083
papers	citations	37 h-index	68 g-index

133	133	133	5946
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Nanoparticles and microparticles for skin drug delivery. Advanced Drug Delivery Reviews, 2011, 63, 470-491.	6.6	684
2	Topical Nano and Microemulsions for Skin Delivery. Pharmaceutics, 2017, 9, 37.	2.0	242
3	Skin models for the testing of transdermal drugs. Clinical Pharmacology: Advances and Applications, 2016, Volume 8, 163-176.	0.8	189
4	Topical and Transdermal Drug Delivery: From Simple Potions to Smart Technologies. Current Drug Delivery, 2019, 16, 444-460.	0.8	182
5	Uterine Papillary Serous Carcinoma: Evaluation of Long-Term Survival in Surgically Staged Patients. Gynecologic Oncology, 1998, 69, 69-73.	0.6	149
6	Non-invasive imaging of skin physiology and percutaneous penetration using fluorescence spectral and lifetime imaging with multiphoton and confocal microscopy. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 77, 469-488.	2.0	147
7	Cimetidine impairs the elimination of theophylline and antipyrine. Gastroenterology, 1981, 81, 19-21.	0.6	131
8	Diagnostic imaging and therapeutic application of nanoparticles targeting the liver. Journal of Materials Chemistry B, 2015, 3, 939-958.	2.9	126
9	Support for the Safe Use of Zinc Oxide Nanoparticle Sunscreens: Lack of Skin Penetration or Cellular Toxicity after RepeatedÂApplication in Volunteers. Journal of Investigative Dermatology, 2019, 139, 308-315.	0.3	123
10	The effect of formulation on the penetration of coated and uncoated zinc oxide nanoparticles into the viable epidermis of human skin in vivo. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 84, 297-308.	2.0	111
11	Quantum dot penetration into viable human skin. Nanotoxicology, 2012, 6, 173-185.	1.6	105
12	Time-Correlated Single Photon Counting For Simultaneous Monitoring Of Zinc Oxide Nanoparticles And NAD(P)H In Intact And Barrier-Disrupted Volunteer Skin. Pharmaceutical Research, 2011, 28, 2920-2930.	1.7	101
13	Short- and Long-Term Tracking of Anionic Ultrasmall Nanoparticles in Kidney. ACS Nano, 2016, 10, 387-395.	7.3	95
14	Applications of multiphoton tomographs and femtosecond laser nanoprocessing microscopes in drug delivery research. Advanced Drug Delivery Reviews, 2011, 63, 388-404.	6.6	92
15	Familial Corticosteroid-Binding Globulin Deficiency Due to a Novel Null Mutation: Association with Fatigue and Relative Hypotension. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3692-3700.	1.8	91
16	Hair follicles contribute significantly to penetration through human skin only at times soon after application as a solvent deposited solid in man. British Journal of Clinical Pharmacology, 2011, 72, 768-774.	1.1	90
17	Topical drug delivery: History, percutaneous absorption, and product development. Advanced Drug Delivery Reviews, 2021, 177, 113929.	6.6	84
18	Analysis of the metabolic deterioration of ex vivo skin from ischemic necrosis through the imaging of intracellular NAD(P)H by multiphoton tomography and fluorescence lifetime imaging microscopy. Journal of Biomedical Optics, 2010, 15, 046008.	1.4	81

#	Article	IF	Citations
19	Gold Nanoparticle Penetration and Reduced Metabolism in Human Skin by Toluene. Pharmaceutical Research, 2011, 28, 2931-2944.	1.7	81
20	Skin Solubility Determines Maximum Transepidermal Flux for Similar Size Molecules. Pharmaceutical Research, 2009, 26, 1974-1985.	1.7	76
21	Comparison of Adrenocorticotropin (ACTH) Stimulation Tests and Insulin Hypoglycemia in Normal Humans: Low Dose, Standard High Dose, and 8-Hour ACTH-(1â€“24) Infusion Tests1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 3648-3655.	1.8	72
22	Comparison of Adrenocorticotropin (ACTH) Stimulation Tests and Insulin Hypoglycemia in Normal Humans: Low Dose, Standard High Dose, and 8-Hour ACTH-(1-24) Infusion Tests. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 3648-3655.	1.8	63
23	Synergistic Skin Penetration Enhancer and Nanoemulsion Formulations Promote the Human Epidermal Permeation of Caffeine and Naproxen. Journal of Pharmaceutical Sciences, 2016, 105, 212-220.	1.6	62
24	Microneedle Enhanced Delivery of Cosmeceutically Relevant Peptides in Human Skin. PLoS ONE, 2014, 9, e101956.	1.1	62
25	Penetration of Nanoparticles into Human Skin. Current Pharmaceutical Design, 2013, 19, 6353-6366.	0.9	59
26	Minoxidil Skin Delivery from Nanoemulsion Formulations Containing Eucalyptol or Oleic Acid: Enhanced Diffusivity and Follicular Targeting. Pharmaceutics, 2018, 10, 19.	2.0	52
27	Relative uptake of minoxidil into appendages and stratum corneum and permeation through human skin in vitro. Journal of Pharmaceutical Sciences, 2010, 99, 712-718.	1.6	51
28	Effect of flexing and massage on in vivo human skin penetration and toxicity of zinc oxide nanoparticles. Nanomedicine, 2016, 11, 1193-1205.	1.7	48
29	Human skin penetration and local effects of topical nano zinc oxide after occlusion and barrier impairment. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 104, 140-147.	2.0	48
30	Delivery of drugs applied topically to the skin. Expert Review of Dermatology, 2012, 7, 383-397.	0.3	46
31	Renal biomarkers predict nephrotoxicity after paraquat. Toxicology Letters, 2013, 222, 280-288.	0.4	46
32	Targeted Topical Delivery of Retinoids in the Management of Acne Vulgaris: Current Formulations and Novel Delivery Systems. Pharmaceutics, 2019, 11, 490.	2.0	46
33	A Randomized Study of a Single Dose of Intramuscular Cholecalciferol in Critically Ill Adults. Critical Care Medicine, 2015, 43, 2313-2320.	0.4	45
34	Alprazolam blocks the naloxone-stimulated hypothalamo-pituitary-adrenal axis in man. Journal of Clinical Endocrinology and Metabolism, 1993, 76, 388-391.	1.8	44
35	Iontophoresis-Mediated Transdermal Permeation of Peptide Dendrimers across Human Epidermis. Skin Pharmacology and Physiology, 2013, 26, 127-138.	1.1	42
36	Real-time histology in liver disease using multiphoton microscopy with fluorescence lifetime imaging. Biomedical Optics Express, 2015, 6, 780.	1.5	42

#	Article	IF	Citations
37	Physiologically Based Pharmacokinetic Model for Long-Circulating Inorganic Nanoparticles. Nano Letters, 2016, 16, 939-945.	4.5	42
38	Use of a glyphosate-based herbicide-induced nephrotoxicity model to investigate a panel of kidney injury biomarkers. Toxicology Letters, 2014, 225, 192-200.	0.4	39
39	Cutaneous Metabolism in Transdermal Drug Delivery. Current Drug Metabolism, 2009, 10, 227-235.	0.7	38
40	Intravital Multiphoton Imaging of the Selective Uptake of Waterâ€Dispersible Quantum Dots into Sinusoidal Liver Cells. Small, 2015, 11, 1711-1720.	5.2	37
41	A Comparison of the Penetration and Permeation of Caffeine into and through Human Epidermis after Application in Various Vesicle Formulations. Skin Pharmacology and Physiology, 2016, 29, 24-30.	1.1	36
42	Mechanistic Evaluation of Enhanced Curcumin Delivery through Human Skin In Vitro from Optimised Nanoemulsion Formulations Fabricated with Different Penetration Enhancers. Pharmaceutics, 2019, 11, 639.	2.0	36
43	Simple and sensitive liquid chromatographyâ€“tandem mass spectrometry methods for quantification of paraquat in plasma and urine: Application to experimental and clinical toxicological studies. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 3047-3052.	1.2	35
44	Association Between Chronic Fatigue Syndrome and the Corticosteroidâ€Binding Globulin Gene ALA SER224Polymorphism. Endocrine Research, 2004, 30, 417-429.	0.6	34
45	Adrenocorticotropin stimulation tests in patients with hypothalamic-pituitary disease: low dose, standard high dose and 8-h infusion tests. Clinical Endocrinology, 2001, 55, 625-633.	1.2	33
46	Acute behavioural disturbance associated with phenibut purchased via an internet supplier. Clinical Toxicology, 2015, 53, 636-638.	0.8	31
47	Alprazolam attenuates vasopressin-stimulated adrenocorticotropin and cortisol release: evidence for synergy between vasopressin and corticotropin-releasing hormone in humans. Journal of Clinical Endocrinology and Metabolism, 1994, 79, 140-144.	1.8	31
48	Aspirin Inhibits Vasopressin-Induced Hypothalamic-Pituitary-Adrenal Activity in Normal Humans. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 812-817.	1.8	31
49	NALOXONE-INDUCED ACTH RELEASE IN MAN IS INHIBITED BY CLONIDINE. Clinical and Experimental Pharmacology and Physiology, 1990, 17, 179-184.	0.9	30
50	Follicular Penetration of Caffeine from Topically Applied Nanoemulsion Formulations Containing Penetration Enhancers: In vitro Human Skin Studies. Skin Pharmacology and Physiology, 2018, 31, 252-260.	1.1	30
51	Space- and time-resolved investigation on diffusion kinetics of human skin following macromolecule delivery by microneedle arrays. Scientific Reports, 2018, 8, 17759.	1.6	27
52	Hypersensitivity of the hypothalamic-pituitary-adrenal axis to naloxone in post-traumatic stress disorder. Biological Psychiatry, 1993, 33, 585-593.	0.7	26
53	Interactions Between the Stimulated Hypothalamic-Pituitary-Adrenal Axis and Leptin in Humans. Journal of Neuroendocrinology, 2001, 12, 141-145.	1.2	24
54	Changes in the redox state and endogenous fluorescence ofin vivohuman skin due to intrinsic and photo-aging, measured by multiphoton tomography with fluorescence lifetime imaging. Journal of Biomedical Optics, 2012, 18, 061217.	1.4	24

#	Article	IF	Citations
55	Development and Evaluation of Lipid Nanoparticles Containing Natural Botanical Oil for Sun Protection: Characterization and in vitro and in vivo Human Skin Permeation and Toxicity. Skin Pharmacology and Physiology, 2018, 31, 1-9.	1.1	24
56	Viscoelastic and Deformation Characteristics of Structurally Different Commercial Topical Systems. Pharmaceutics, 2021, 13, 1351.	2.0	24
57	Adrenocorticotropin Hyperresponsiveness in Myotonic Dystrophy Following Oral Fenfluramine Administration. Journal of Neuroendocrinology, 1991, 3, 69-73.	1.2	23
58	Enhanced sonophoretic delivery of 5â€aminolevulinic acid: preliminary human ex vivo permeation data. Skin Research and Technology, 2013, 19, e283-9.	0.8	23
59	Iontophoretic skin permeation of peptides: an investigation into the influence of molecular properties, iontophoretic conditions and formulation parameters. Drug Delivery and Translational Research, 2014, 4, 222-232.	3.0	22
60	A Synergistic Adrenocorticotropin Response to Naloxone and Vasopressin in Normal Humans: Evidence That Naloxone Stimulates Endogenous Corticotropin-Releasing Hormone. Neuroendocrinology, 1995, 61, 198-206.	1.2	21
61	Zinc oxide nanoparticle removal from wounded human skin. Nanomedicine, 2013, 8, 1751-1761.	1.7	21
62	Mechanistic Evaluation of Hydration Effects on the Human Epidermal Permeation of Salicylate Esters. AAPS Journal, 2017, 19, 180-190.	2.2	20
63	Deformable liposomes as enhancer of caffeine penetration through human skin in a Franz diffusion cell test. International Journal of Cosmetic Science, 2021, 43, 1-10.	1.2	20
64	Enhanced transdermal delivery of 5â€aminolevulinic acid and a dipeptide by iontophoresis. Biopolymers, 2011, 96, 166-171.	1.2	19
65	The Human Stratum Corneum Prevents Small Gold Nanoparticle Penetration and Their Potential Toxic Metabolic Consequences. Journal of Nanomaterials, 2012, 2012, 1-8.	1.5	19
66	ZnO:SBA-15 Nanocomposites for Potential Use in Sunscreen: Preparation, Properties, Human Skin Penetration and Toxicity. Skin Pharmacology and Physiology, 2019, 32, 32-42.	1.1	19
67	Naloxoneâ€induced ACTH release: mechanism of action in humans. Clinical Endocrinology, 1995, 43, 423-424.	1.2	18
68	Permeation of topically applied Magnesium ions through human skin is facilitated by hair follicles. Magnesium Research, 2016, 29, 35-42.	0.4	18
69	Estimating Maximal In Vitro Skin Permeation Flux from Studies Using Non-sink Receptor Phase Conditions. Pharmaceutical Research, 2016, 33, 2180-2194.	1.7	18
70	Metal peptide complexes: preparations and proton and carbon-13 NMR spectra of cobalt(III) tripeptide complexes. Inorganic Chemistry, 1980, 19, 3496-3502.	1.9	17
71	Determination of trovafloxacin and marbofloxacin in sheep plasma samples by HPLC using UV detection. Journal of Pharmaceutical and Biomedical Analysis, 2012, 62, 220-223.	1.4	17
72	Cellular metabolism and pore lifetime of human skin following microprojection array mediation. Journal of Controlled Release, 2019, 306, 59-68.	4.8	17

#	Article	IF	Citations
73	Cimetidine use in children with cystic fibrosis: Inhibition of hepatic drug metabolism. Journal of Pediatrics, 1982, 100, 325-327.	0.9	16
74	Modeling percutaneous absorption for successful drug discovery and development. Expert Opinion on Drug Discovery, 2020, 15, 1181-1198.	2.5	16
75	The Insulin Hypoglycemia Test: Hypoglycemic Criteria and Reproducibility. Journal of Neuroendocrinology, 2001, 13, 524-530.	1.2	15
76	Effects of magnesium deficiency â€“ More than skin deep. Experimental Biology and Medicine, 2014, 239, 1280-1291.	1.1	14
77	Cardiovascular toxicity with levetiracetam overdose. Clinical Toxicology, 2016, 54, 152-154.	0.8	14
78	Permeation Mechanism of Caffeine and Naproxen through in vitro Human Epidermis: Effect of Vehicles and Penetration Enhancers. Skin Pharmacology and Physiology, 2019, 32, 132-141.	1.1	14
79	Beware of blotting paper hallucinogens: severe toxicity with NBOMes. Medical Journal of Australia, 2015, 203, 266-267.	0.8	13
80	Aspirin increases the human hypothalamic-pituitary-adrenal axis response to naloxone stimulation. Journal of Clinical Endocrinology and Metabolism, 1993, 77, 404-408.	1.8	13
81	Cimetidineâ€theophylline interaction in patients with chronic obstructive airways disease. Medical Journal of Australia, 1984, 140, 279-280.	0.8	13
82	Evaluation of Quantum Dot Skin Penetration in Porcine Skin: Effect of Age and Anatomical Site of Topical Application. Skin Pharmacology and Physiology, 2019, 32, 182-191.	1.1	12
83	Development of an Oil-in-Water Self-Emulsifying Microemulsion for Cutaneous Delivery of Rose Bengal: Investigation of Anti-Melanoma Properties. Pharmaceutics, 2020, 12, 947.	2.0	12
84	Noninvasive in vivo human multiphoton microscopy: a key method in proving nanoparticulate zinc oxide sunscreen safety. Journal of Biomedical Optics, 2020, 25, 1.	1.4	12
85	Kidney biomarkers in MCPA-induced acute kidney injury in rats: Reduced clearance enhances early biomarker performance. Toxicology Letters, 2014, 225, 467-478.	0.4	11
86	Altered hypothalamic-pituitary-adrenal axis responsiveness in myotonic dystrophy: in vivo evidence for abnormal dihydropyridine-insensitive calcium transport. Journal of Clinical Endocrinology and Metabolism, 1993, 76, 1433-1438.	1.8	11
87	NALOXONE STIMULATION OF ACTH SECRETION DURING PETROSAL SINUS SAMPLING IN CUSHING'S SYNDROME. Clinical and Experimental Pharmacology and Physiology, 1993, 20, 299-302.	0.9	10
88	Non-formulation Parameters That Affect Penetrant-Skin-Vehicle Interactions and Percutaneous Absorption. , 2017, , 45-75.		10
89	Early Rise In Blood Pressure Following Administration Of Adrenocorticotropic Hormone-[1-24] In Humans. Clinical and Experimental Pharmacology and Physiology, 2001, 28, 773-775.	0.9	9
90	Letter to the Editor: Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change. Psychoneuroendocrinology, 2004, 29, 563-564.	1.3	9

#	Article	IF	Citations
91	The kinetics of oral cimetidine in children with cystic fibrosis [letter]. British Journal of Clinical Pharmacology, 1981, 12, 248-249.	1.1	8
92	The application of molecular structural predictors of intestinal absorption to screening of compounds for transdermal penetration. Journal of Pharmacy and Pharmacology, 2010, 62, 750-755.	1.2	8
93	Using a simple equation to predict the microporation-enhanced transdermal drug flux. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 127, 12-18.	2.0	8
94	Adrenocorticotropin hyperresponse to the corticotropin-releasing hormone-mediated stimulus of naloxone in patients with myotonic dystrophy. Journal of Clinical Endocrinology and Metabolism, 1995, 80, 179-184.	1.8	8
95	The effect of desipramine on basal and naloxone-stimulated cortisol secretion in humans: interaction of two drugs acting on noradrenergic control of adrenocorticotropin secretion. Journal of Clinical Endocrinology and Metabolism, 1995, 80, 802-806.	1.8	8
96	ADRENALINE INFUSION AND ADRENOCORTICOTROPHIN (ACTH) AND CORTISOL RELEASE IN NORMOTENSIVE AND HYPERTENSIVE MAN. Clinical and Experimental Pharmacology and Physiology, 1987, 14, 203-208.	0.9	7
97	Relating transdermal delivery plasma pharmacokinetics with in vitro permeation test (IVPT) findings using diffusion and compartment-in-series models. Journal of Controlled Release, 2021, 334, 37-51.	4.8	7
98	INHIBITION OF SEROTONIN-INDUCED ACTH RELEASE IN MAN BY CLONIDINE. Clinical and Experimental Pharmacology and Physiology, 1988, 15, 293-298.	0.9	6
99	L-TYPE CALCIUM CHANNELS AND CRH-MEDIATED ACTH AND CORTISOL RELEASE IN HUMANS. Clinical and Experimental Pharmacology and Physiology, 1991, 18, 303-307.	0.9	6
100	Effect of Exogenous Arginine Vasopressin on Adrenocorticotropin and Cortisol Release in Myotonie Dystrophy Patients: Delayed Responses of Normal Magnitude. Journal of Neuroendocrinology, 1991, 3, 65-68.	1.2	6
101	EFFECT OF SODIUM VALPROATE ON NALOXONE-STIMULATED ACTH AND CORTISOL RELEASE IN HUMANS. Clinical and Experimental Pharmacology and Physiology, 1995, 22, 441-443.	0.9	6
102	NEW DIAGNOSTIC TESTS FOR CUSHING'S SYNDROME: USES OF NALOXONE, VASOPRESSIN AND ALPRAZOLAM. Clinical and Experimental Pharmacology and Physiology, 1996, 23, 579-581.	0.9	6
103	The Use of Naloxone for Investigating Disorders of the Hypothalamic-Pituitary-Adrenal Axis. , 1999, 9, 161-182.		6
104	Analysing the Skin Barrier from Down Under. Skin Pharmacology and Physiology, 2013, 26, 254-262.	1.1	6
105	POTENTIATION OF FENFLURAMINE-INDUCED ACTH RELEASE IN MAN BY NALOXONE. Clinical and Experimental Pharmacology and Physiology, 1989, 16, 263-267.	0.9	5
106	Inhibition of Naloxoneâ€Stimulated Adrenocorticotropin Release by Alprazolam in Myotonic Dystrophy Patients. Journal of Neuroendocrinology, 1998, 10, 391-395.	1.2	5
107	Intradermal Proximal Field Block: An Innovative Anesthetic Technique for Levonorgestrel Implant Removal. Obstetrics and Gynecology, 1998, 91, 294-297.	1.2	5
108	Random measurements of adiponectin and <scp>IL</scp>â€6 may not be indicative of the 24â€h profile in critically ill patients. Clinical Endocrinology, 2013, 79, 892-898.	1.2	5

#	Article	IF	Citations
109	2-Methyl-4-chlorophenoxyacetic acid and bromoxynil herbicide death. Clinical Toxicology, 2015, 53, 486-488.	0.8	5
110	Using deconvolution to understand the mechanism for variable plasma concentrationâ€“time profiles after intramuscular injection. International Journal of Pharmaceutics, 2015, 481, 71-78.	2.6	4
111	NIFEDIPINE BLOCKS ACTH AND CORTISOL RELEASE IN MAN. Clinical and Experimental Pharmacology and Physiology, 1989, 16, 257-261.	0.9	3
112	DIURNAL EFFECTS OF FLUOXETINE AND NALOXONE ON THE HUMAN HYPOTHALAMIC-PITUITARY-ADRENAL AXIS. Clinical and Experimental Pharmacology and Physiology, 1997, 24, 421-423.	0.9	3
113	The pharmacokinetics and pharmacodynamics of severe aldicarb toxicity after overdose. Clinical Toxicology, 2015, 53, 633-635.	0.8	3
114	Efficacy, Safety and Targets in Topical and Transdermal Active and Excipient Delivery. , 2017, , 369-391.		3
115	The Influence of Emollients on Dermal and Transdermal Drug Delivery. , 2017, , 77-93.		3
116	Bathing Does Not Facilitate Human Skin Penetration or Adverse Cellular Effects of Nanoparticulate Zinc Oxide Sunscreens after TopicalÂApplication. Journal of Investigative Dermatology, 2020, 140, 1656-1659.	0.3	3
117	Paradoxical inhibition by aspirin of naloxone-induced adrenocorticotropin secretion in myotonic dystrophy. Journal of Clinical Endocrinology and Metabolism, 1994, 78, 1424-1427.	1.8	3
118	PITUITARY-ADRENAL RESPONSES TO COMBINED ORAL D-FENFLURAMINE AND INTRAVENOUS NALOXONE IN HUMANS. Clinical and Experimental Pharmacology and Physiology, 1998, 25, 621-623.	0.9	2
119	Cellâ€mediated immunity in combat veterans with postâ€traumatic stress disorder. Medical Journal of Australia, 1994, 161, 287-288.	0.8	2
120	CRH-mediated pituitary-adrenal responses are inhibited by nifedipine in humans. NeuroReport, 1992, 3, 373.	0.6	1
121	EFFECT OF FLUMAZENIL ON BASAL AND NALOXONE-STIMULATED ACTH AND CORTISOL RELEASE IN HUMANS. Clinical and Experimental Pharmacology and Physiology, 1994, 21, 157-161.	0.9	1
122	Evidence for extra-renal production of 1Î±,25(OH)2D3 in critical illness: a preliminary study. Intensive Care Medicine, 2013, 39, 1505-1506.	3.9	1
123	Feasibility of multiphoton microscopy-based quantification of antibiotic uptake into neutrophil granulocytes. Journal of Biomedical Optics, 2013, 18, 076003.	1.4	1
124	Formulation Effects in Percutaneous Absorption. , 2015, , 109-134.		1
125	Targeting the Pilosebaceous Gland. , 2007, , 169-187.		0